Smad6 Activators
Smad6 activators are a category of chemical agents that are specifically designed to modulate the activity of Smad6, a member of the SMAD family of proteins. Smad6, in particular, functions as an intracellular signaling molecule that plays a pivotal role in the transforming growth factor-beta (TGF-β) signaling pathway. This pathway is highly conserved across many species and is instrumental in regulating a wide array of cellular processes, including proliferation, differentiation, and apoptosis. Smad6, unlike its relatives which transduce TGF-β signals, acts as an inhibitory SMAD (I-SMAD) and is involved in the negative feedback regulation of TGF-β signaling. By activating Smad6, these chemicals enhance its ability to interfere with the propagation of signals that normally proceed through the SMAD-dependent pathway.
The mechanism by which Smad6 activators exert their influence involves the upregulation of Smad6 activity, which in turn leads to the inhibition of the phosphorylation and activation of receptor-regulated SMADs (R-SMADs). Smad6 achieves this by competing with R-SMADs for interaction with type I TGF-β receptors, thereby preventing their activation. Additionally, Smad6 can recruit ubiquitin ligases to the activated receptor complex, promoting the degradation of R-SMADs and further dampening the signal transduction. Smad6 activators, therefore, result in the amplification of a negative feedback loop within the TGF-β signaling cascade.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189, a BMP type I receptor inhibitor, indirectly activates Smad6 by blocking BMP signaling. By inhibiting BMP receptor activity, LDN-193189 prevents Smad6 degradation, allowing it to accumulate and inhibit BMP-induced Smad1/5 phosphorylation. This indirect activation of Smad6 modulates BMP signaling pathways and cellular responses. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542, a TGF-β receptor inhibitor, indirectly activates Smad6 by disrupting TGF-β signaling. Inhibition of TGF-β receptors by SB-431542 prevents Smad6 degradation, leading to increased Smad6 levels. This indirect activation of Smad6 modulates TGF-β signaling pathways, influencing cellular processes regulated by Smad6, such as inflammation and tissue homeostasis. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin, an AMP-activated protein kinase (AMPK) inhibitor, indirectly activates Smad6 by blocking BMP type I receptor activity. Inhibition of BMP signaling by Dorsomorphin prevents Smad6 degradation, allowing it to accumulate and inhibit BMP-induced Smad1/5 phosphorylation. This indirect activation of Smad6 modulates BMP signaling pathways and cellular responses. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01, a TGF-β receptor inhibitor, indirectly activates Smad6 by disrupting TGF-β signaling. Inhibition of TGF-β receptors by A83-01 prevents Smad6 degradation, leading to increased Smad6 levels. This indirect activation of Smad6 modulates TGF-β signaling pathways, influencing cellular processes regulated by Smad6, such as immune responses and tissue repair. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117, a BMP type I receptor inhibitor, indirectly activates Smad6 by blocking BMP signaling. Inhibition of BMP receptor activity by LDN-214117 prevents Smad6 degradation, allowing it to accumulate and inhibit BMP-induced Smad1/5 phosphorylation. This indirect activation of Smad6 modulates BMP signaling pathways, affecting cellular responses regulated by Smad6. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY2157299, a TGF-β receptor inhibitor, indirectly activates Smad6 by disrupting TGF-β signaling. Inhibition of TGF-β receptors by Galunisertib prevents Smad6 degradation, leading to increased Smad6 levels. This indirect activation of Smad6 modulates TGF-β signaling pathways, influencing cellular processes regulated by Smad6, such as fibrosis and tissue remodeling. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
SD-208, a TGF-β receptor inhibitor, indirectly activates Smad6 by disrupting TGF-β signaling. Inhibition of TGF-β receptors by SD-208 prevents Smad6 degradation, leading to increased Smad6 levels. This indirect activation of Smad6 modulates TGF-β signaling pathways, influencing cellular processes regulated by Smad6, such as inflammation and tissue homeostasis. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $327.00 $1377.00 | 2 | |
SB-505124, a TGF-β receptor inhibitor, indirectly activates Smad6 by disrupting TGF-β signaling. Inhibition of TGF-β receptors by SB-505124 prevents Smad6 degradation, leading to increased Smad6 levels. This indirect activation of Smad6 modulates TGF-β signaling pathways, influencing cellular processes regulated by Smad6, such as cell migration and tissue development. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197, a TGF-β receptor inhibitor, indirectly activates Smad6 by disrupting TGF-β signaling. Inhibition of TGF-β receptors by EW-7197 prevents Smad6 degradation, leading to increased Smad6 levels. This indirect activation of Smad6 modulates TGF-β signaling pathways, influencing cellular processes regulated by Smad6, such as tissue repair and inflammation. | ||||||